Weight Loss Sale

Fibromyalgia References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Burgmer M, Pogatzki-Zhan E, Gaubitz M, et al. Altered brain activity during pain processing in fibromyalgia. Neuroimage. 2009 Jan 15;44(2):502-8. Epub 2008 Sep 24.
  2. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007 Jun;36(6):339-56.
  3. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333-1343.
  4. Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetics aspects of fibromyalgia syndrome. Arthritis Res Ther 2006; 8:218-22.
  5. Diatchenko L, Nackley AG, Slade GD, et al. Idiopathic pain disorders--pathways of vulnerability. Pain. 2006 Aug;123(3):226-30. Epub 2006 Jun 13.
  6. Buskila D, Press J, and Abu-shakra M. Fibromyalgia in systemic lupus erythematosus: prevalence and clinical implications. Clin Rev Allergy Immunol. 2003 Aug;25(1):25-8.
  7. Thompson ME and Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Curr Pain Headache Rep. 2003 Oct;7(5):342-7.
  8. Wolfe F, Cathey MA, and Kleinheksel SM. Fibrositis (Fibromyalgia) in rheumatoid arthritis. J Rheumatol. 1984 Dec;11(6):814-8.
  9. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59(7):952-960.
  10. Arnold LM, Clauw DJ, McCarberg BH. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011;86(5):457-464.
  11. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: an epidemiological study supporting migraine as part of the fibromyalgia syndrome. Clin Rheumatol. 2005;24(6):595-601.
  12. Nordqvist C. What Is Fibromyalgia? What Causes Fibromyalgia? Available at: http://www.medicalnewstoday.com/articles/147083.php Accessed 3/21/2012.
  13. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388-2395.
  14. Rico-Villademoros F, Calandre EP, Rodriguez-Lopez CM, et al. Sexual functioning in women and men with fibromyalgia. J Sex Med. 2012 Feb;9(2):542-9.
  15. Arnold LM, Crofford L3, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73(1):114-120.
  16. Goldenberg, MD. Clinical manifestations and diagnosis of fibromyalgia in adults. In: UpToDate, Peter H Schur, MD, Paul L Romain, MD (Eds), UpToDate, Waltham, MA, 2011.
  17. Wolfe F, Clauw D, Fitzcharles MA, Goldenberg D, Katz RS, Mease P. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62: 600–10
  18. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med. 1999;159(8):777-785.
  19. Dadabhoy D, Crofford LL, Spaeth M, Russell IJ, Clauw DJ. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther 2008; 10:211.
  20. Braz Ade S, de Paula AP, Diniz Mde F, de Almeida RN. Non-pharmacological therapy and complementary and alternative medicine in fibromyalgia. Rev Bras Reumatol. 2011;51(3):269-282.
  21. Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clin Proc. 2011;86(9):907-911.
  22. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
  23. Terhorst L, Schneider MJ, Kim KH, et al. Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. J Manipulative Physiol Ther. 2011 Sep;34(7):483-96. Epub 2011 Jun 24.
  24. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am. 2002;28(2):389-404.
  25. Sadreddini S, Molaeefard M, Noshad H, et al. Efficacy of Raloxifen in treatment of fibromyalgia in menopausal women. Eur J Intern Med. 2008 Jul;19(5):350-5.
  26. Sarac AJ, Gur A. Complementary and alternative medical therapies in fibromyalgia. Curr Pharm Des. 2006;12(1):47-57.
  27. Cuatrecasas G, Gonzalez MJ, Alegre C, et al. High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab. 2010;95(9):4331-4337.
  28. Terry R, Perry R, Ernst E. An overview of systematic reviews of complementary and alternative medicine for fibromyalgia. Clin Rheumatol. 2012;31(1):55-66.
  29. Cuatrecasas G. Fibromyalgic syndromes: could growth hormone therapy be beneficial? Pediatr Endocrinol Rev. 2009;4:529-533.
  30. Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2012;741746:2.
  31. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3(4):271-280.
  32. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia - Increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol. 2012;242(1-2):33-38.
  33. Lucas HJ, Brauch CM, Settas L, Theoharides TC. Fibromyalgia--new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol. 2006;19(1):5-10.
  34. Calder PC. Omega-3 Fatty acids and inflammatory processes. Nutrients. 2010;2(3):355-374.
  35. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16(6):4567-4598.
  36. Sengupta K, Kolla JN, Krishnaraju AV, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem. 2011;354(1-2):189-197.
  37. Moldofsky H. Rheumatic manifestations of sleep disorders. Curr Opin Rheumatol. 2010;22(1):59-63.
  38. Prados G, Miro E. Fibromyalgia and sleep: a review. Rev Neurol. 2012;54(4):227-240.
  39. Arnold LM, Clauw DJ. Fibromyalgia syndrome: practical strategies for improving diagnosis and patient outcomes: Am J Med. 2010 Jun;123(6):S2.
  40. Hussain SA, Al K, II, Jasim NA, Gorial FI. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res. 2011;50(3):267-271.
  41. Reiter RJ, Acuna-Castroviejio D, Tan DX. Melatonin therapy in fibromyalgia. Curr Pain Headache Rep 2007; 11:339–342.
  42. Spaeth M, Rizzi M, Sarzi-Puttini P. Fibromyalgia and sleep. Best Pract Res Clin Rheumatol. 2011;25(2):227-239.
  43. Leger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379-389.
  44. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):730-43.
  45. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol. 2007 Aug;83(1):84-92.
  46. Le Goff P. Is fibromyalgia a muscle disorder? Bone Spine. 2006 May;73(3):239-42.
  47. Cordero MD, et al. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem. 2010a Sep;43(13-14):1174-6.
  48. Abdullah M, et al. Mitochondrial myopathy presenting as fibromyalgia: a case report. J Med Case Reports. 2012 Feb 10;6(1):55.
  49. Cordero MD, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. 2010b;12(1):R17.
  50. Saber AA, Boros MJ, Mancl T, Elgamal MH, Song S, Wisadrattanapong T. The effect of laparoscopic Roux-en-Y gastric bypass on fibromyalgia. Obes Surg. 2008;18(6):652-655.
  51. Okifuji A, Bradshaw DH, Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol. 2009;28(4):475-478.
  52. Okifuji A, Donaldson GW, Barck L, Fine PG. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. J Pain. 2010;11(12):1329-1337.
  53. Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int. 2011;31(11):1403-1408.
  54. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-227.
  55. Henningsen P, Zipfel S, Herzog W. Management of functional somatic syndromes. Lancet. 2007;369:946–55.
  56. Tits M. [Fibromyalgia and physical therapy]. Rev Med Brux. 2011 Sep;32(4):393-7.
  57. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67(4):536-541.
  58. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am 2009; 35:393.
  59. de Miquel CA, Campayo JG, Florez MT, et al. Interdisciplinary consensus document for the treatment of fibromyalgia. Actas Esp Psiquiatr. 2010;38(2):108-120.
  60. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. American Journal of Health-System Pharmacy. July 15, 2011 2011;68(14):1307-1319.
  61. Argoff CE. Pharmacologic management of chronic pain. J Am Osteopathic Assoc. 2002;102(9suppl3):521–526.
  62. Luciano JV, Martinez N, Penarrubia-Maria MT, et al. Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial. Clin J Pain. 2011;27(5):383-391.
  63. Pfeiffer A, Thompson JM, Nelson A, et al. Effects of a 1.5-day multidisciplinary outpatient treatment program for fibromyalgia: a pilot study. Am J Phys Med Rehabil. 2003;82(3):186-191.
  64. Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010;151(2):280-295.
  65. Crofford LJ, Appleton BE. Complementary and alternative therapies for fibromyalgia. Curr Rheumatol Reports 2001; 3:147-56.
  66. Arranz LI, Canela MA, Rafecas M. Fibromyalgia and nutrition, what do we know? Rheumatol Int. 2010;30(11):1417-1427.
  67. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. Redox Rep. 2006;11(3):131-135.
  68. Bagis S, Tamer L, Sahin G, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int. 2005;25(3):188-190.
  69. Sendur OF, Turan Y, Tastaban E, et al. Serum antioxidants and nitric oxide levels in fibromyalgia: a controlled study. Rheumatol Int. 2009;29(6):629-633.
  70. U.S. Department of Agriculture. USDA database for the Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods. 2007. Available at: http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Articles/AICR07_ORAC.pdf
  71. Carson JW, Carson KM, Jones KD, Bennett RM, Wright CL, Mist SD. A pilot randomized controlled trial of the Yoga of Awareness program in the management of fibromyalgia. Pain. 2010;151(2):530-539.
  72. Schmidt S, Grossman P, Schwarzer B, Jena S, Naumann J, Walach H. Treating fibromyalgia with mindfulness-based stress reduction: results from a 3-armed randomized controlled trial. Pain. 2011;152(2):361-369.
  73. Wang C, Schmid CH, Rones R, et al. A randomized trial of tai chi for fibromyalgia. N Engl J Med. 2010;363(8):743-754.
  74. Sendur OF, Tastaban E, Turan Y, Ulman C. The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia. Rheumatol Int. 2008;28(11):1117-1121.
  75. Bagis S, Karabiber M, As I, et al. Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia? Rheumatol Int. 2012 Jan 22. [Epub ahead of print].
  76. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:667-83.
  77. Arranz LI, Canela MA, Rafecas M. Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. Rheumatol Int. 2011;22:22.
  78. Mahdi AA, et al. Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys. 2011 Apr;48(2):82-7.
  79. Jacobsen S, et al. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 1991;20(4):294-302.
  80. Albert JE, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec;24(6):661-4.
  81. Alok R, Das SK, Agarwal GG, et al. Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol. 2011 Nov-Dec;29(6 Suppl 69):S70-2. Epub 2012 Jan 3.
  82. Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006;12(9):857-862.
  83. Flanigan R, et al. D-ribose aids fatigue in aging adults. J Altern Complement Med. 2010 May;16(5):529-30.
  84. Gebhart B, Jorgenson JA. Benefit of ribose in a patient with fibromyalgia. Pharmacotherapy. 2004 Nov;24(11):1646-8.
  85. Merchant RE, et al. Nutritional supplementation with Chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res. 2000 May;14(3):167-73.
  86. Schwarz MJ, et al. Evidence for an altered tryptophan metabolism in fibromyalgia. Neurobiol Dis. 2002 Dec;11(3):434-42.
  87. Caruso I, et al. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9.
  88. Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res. 1992 Apr;20(2):182-9.
  89. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37(1):31-37.
  90. Jung HJ, Park EH, Lim CJ. Evaluation of anti-angiogenic, anti-inflammatory and antinociceptive activity of coenzyme Q(10) in experimental animals. J Pharm Pharmacol. 2009;61(10):1391-1395.
  91. Cordero MD, Alcocer-Gomez E, de Miguel M, et al. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients. Mitochondrion. 2011;11(4):623-625.
  92. Abdul HM, Calabrese V, Calvani M, Butterfield DA. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res. 2006;84(2):398-408.
  93. Rossini M, Di Munno O, Valentini G, et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007;25(2):182-188.
  94. Ozgocmen S, Catal SA, Ardicoglu O, Kamanli A. Effect of omega-3 fatty acids in the management of fibromyalgia syndrome: Int J Clin Pharmacol Ther. 2000 Jul;38(7):362-3.
  95. Ko GD, et al. Omega-3 fatty acids for neuropathic pain: case series. Clin J Pain. 2010 Feb;26(2):168-72.
  96. Bhatty SA, Shaikh NA, Irfan M, et al. Vitamin D deficiency in fibromyalgia. J Pak Med Assoc. 2010;60(11):949-951.
  97. Olama SM, Senna MK, Elarman MM, et al. Serum vitamin D level and bone mineral density in premenopausal Egyptian women with fibromyalgia. Rheumatol Int. 2013 Jan;33(1):185-92.
  98. Matthana MH. The relation between vitamin D deficiency and fibromyalgia syndrome in women. Saudi Med J. 2011 Sep;32(9):925-9.
  99. Skarpanska-Stejnborn A, et al. Effects of oral supplementation with plant superoxide dismutase extract on selected redox parameters and an inflammatory marker in a 2,000-m rowing-ergometer test. Int J Sport Nutr Exerc Metab. 2011 Apr;21(2):124-34.
  100. Akkus S, et al. Levels of lipid peroxidation, nitric oxide, and antioxidant vitamins in plasma of patients with fibromyalgia. Cell Biochem Funct. 2009 Jun;27(4):181-5.
  101. Wahner-Roedler DL, Elkin PL, Vincent A, et al. Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. Mayo Clin Proc. 2005;80(1):55-60.
  102. Karajibani M, et al. Effect of vitamin E and C supplements on antioxidant defense system in cardiovascular disease patients in Zahedan, southeast Iran. J Nutr Sci Vitaminol (Tokyo). 2010;56(6):436-40.
  103. Regland B, et al. Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scand J Rheumatol. 1997;26(4):301-7.
  104. Gaby AR. Intravenous nutrient therapy: the "Myers' cocktail". Altern Med Rev. 2002 Oct;7(5):389-403.
  105. Ali A, Njike VY, Northrup V, et al. Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study. J Altern Complement Med. 2009 Mar;15(3):247-57.
  106. Depeint F, et al. Mitochondrial function and toxicity: role of B vitamins on the one-carbon transfer pathways. Chem Biol Interact. 2006 Oct 27;163(1-2):113-32. Epub 2006 May 24.
  107. Forsyth LM, Preuss HG, MacDowell AL, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999 Feb;82(2):185-91.
  108. Birkmayer GD, Kay GG, Vurre E, et al. [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]. Wien Med Wochenschr. 2002;152(17-18):450-4.
  109. Demarin V, Podobnik SS, Storga-Tomic D, et al. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp Clin Res. 2004;30(1):27-33.
  110. Birkmayer JG, Vrecko C, Volc D, et al. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl. 1993;146:32-5.